Shahab Khan, MD
Hematology & Oncology · Houston, TXNPI 1548292980
Payments from drug & device makers
Across 134 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$342
- Merck$308
- Incyte Corporation$224
- Amgen$221
- Pfizer$180
- AstraZeneca$165
- plus $2K from 30 others
What the payments were for
- Food & beverage$2,91296%
- Education$1244%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $342 |
| Merck | 14 | $308 |
| Incyte Corporation | 10 | $224 |
| Amgen | 9 | $221 |
| Pfizer | 7 | $180 |
| AstraZeneca(2 entities) | 8 | $165 |
| Eisai Inc. | 7 | $165 |
| Pharmaessentia USA Corporation | 6 | $152 |
| Sanofi | 6 | $148 |
| Johnson & Johnson(2 entities) | 7 | $127 |
| Genentech USA, Inc. | 4 | $103 |
| GSK | 3 | $86 |
| Jazz Pharmaceuticals Inc. | 3 | $82 |
| Sirtex Medical Inc | 4 | $77 |
| Taiho Oncology, Inc. | 3 | $67 |
| Bristol Myers Squibb | 3 | $67 |
| Rigel Pharmaceuticals, Inc. | 2 | $57 |
| Novartis | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Deciphera Pharmaceuticals Inc. | 1 | $35 |
| Gilead | 1 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Astellas Pharma US Inc | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Inari Medical, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Mylan Institutional Inc. | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Organon | 2 | $16 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$3,037 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MvasiBevacizumab-Awwb | 69 | $295,292 |
| PomalystPomalidomide | 11 | $239,205 |
| KeytrudaPembrolizumab | 15 | $167,430 |
| EliquisApixaban | 238 | $162,811 |
| ErbituxCetuximab | 27 | $140,789 |
| XgevaDenosumab | 40 | $128,735 |
| PerjetaPertuzumab | 16 | $126,408 |
| NplateRomiplostim | 12 | $123,651 |
| OpdivoNivolumab | 12 | $113,247 |
| ImfinziDurvalumab | 17 | $113,210 |
| HerceptinTrastuzumab | 14 | $82,002 |
| Abiraterone Acetate | 40 | $76,111 |
| XareltoRivaroxaban | 55 | $50,810 |
| UdenycaPegfilgrastim-Cbqv | 12 | $49,561 |
| VenclextaVenetoclax | 11 | $45,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenMvasi, Xgeva, Nplate | $221 | $547,678121 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Opdivo | $342 | $352,45223 claims |
| MerckKeytruda | $308 | $167,43015 claims |
| PfizerEliquis | $180 | $162,811238 claims |
| Lilly USA, LLCErbitux | $25 | $140,78927 claims |
| AstraZenecaImfinzi | $165 | $113,21017 claims |
| Johnson & JohnsonXarelto | $127 | $50,81055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Houston
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Philip ThompsonHouston$13.6M
- Naval DaverHouston$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.